

Financial Summary for the group

KSEK	2022-10-01	2021-10-01	2022-01-01	2021-01-01
	2022-12-31	2021-12-31	2022-12-31	2021-12-31
Net turnover	0	0	0	0
Profit/loss before tax	-6 226	-13 985	-42 468	-45 046
Total assets	52 527	46 128	52 527	46 128
Earnings per share before and after dilution (SEK)	-0,06	-0,22	-0,44	-0,73
Cash and cash equivalents as per period end	29 246	29 357	29 246	29 357
Equity ratio as per period end	89,5%	85,0%	89,5%	85,0%

Significant Events

Significant events during the fourth quarter of 2022

- Nomination committee appointed for Cyxone Annual General Meeting 2023
- Cyxone receive ethical and regulatory approval from Hungary to start clinical Phase 2b study in RA
- Cyxone appoints Carl-Magnus Högerkorp as permanent CEO

Significant events after the end of the period

- Cyxone advances the patent portfolio for Rabeximod
- Cyxone receive ethical and regulatory approval from Georgia to conduct clinical Phase 2b study in RA

Significant events during the first to the third quarter of 2022

- Cyxone stepped up activities and collaborates with global CRO on the RA study.
- Cyxone engaged contract development and manufacturing organization for production of T20K.
- Cyxone announced the outcome of the rights issue. In total, the rights issue was subscribed to approximately 91 percent.
- Cyxone announced that the company's CMO is resigning at his own request due to personal reasons.
- Tara Heitner steps down as CEO of Cyxone AB
- Carl-Magnus Högerkorp is appointed as interim CEO
- The board has decided to employ Bert Junno as working chairman to assist in investor relations, legal and contractual technical areas
- Cyxone files regulatory submission to start clinical phase 2b study with Rabeximod
- Cyxone filed submission to start clinical Phase 2b study in Poland and Georgia
- Cyxone received regulatory approval to start clinical Phase 2b study in Rheumatoid Arthritis in Poland
- Cyxone appointed Erika Samuelsson as Chief Development Officer
- Ola Skanung will take over the role as CFO from Henrik Hang as of November 2022

one

Follow our news and information about our presence at investor events via Nasdaq First North Growth Market and the company's website: www.cyxone.com.

This is a translation of the original Swedish version of the interim report. In case of any discrepancy between this translation and the Swedish original, the latter shall prevail.

The information was submitted for publication, through the agency of the contact person set out above, at 08.30 a.m. CEST on 17th of February 2023.

Carl-Magnus Högerkorp, CEO
Mobile no.: [+46 70 781 88 12](tel:+46707818812)
E-mail: carl.hogerkorp@cyxone.com

CEO Carl-Magnus Högerkorp comments

The recent advances during Q4 include additional ethical and regulatory approval for our upcoming Phase 2b APPRAIS study in moderate to severe rheumatoid arthritis, now covering Poland, Hungary and Georgia.

“We see that there is great interest in our projects and the planned R&D activities, and I am confident that we will be able to build on this in a positive way.”

Carl-Magnus Högerkorp, CEO Cyhone AB



The Phase 2b study APPRAIS continues on a positive track

The preparations for the planned Phase 2b study APPRAIS in moderate to severe patients with rheumatoid arthritis continues with new ethical and regulatory approvals, strengthening our confidence in the protocol and the study design. In December regulatory approvals from the Hungarian Medical Product Agency (National Institute of Pharmacy and Nutrition - OGYEI) were obtained, and in February ethical and regulatory approvals were obtained from the Georgian Medical Product Agency (LEPL Regulation Agency for Medical and Pharmaceutical Activities). In addition to Georgia and Hungary, the study is approved by the Polish Medical Product Agency (Office for Registration of Medicinal Products, Medical devices and Biocides) and central ethics committee.

During the autumn we have also engaged in conducting a follow-up non-clinical study which was recommended by the American Medical Product Agency (Food and Drug Administration - FDA) following a pre-IND meeting held in June 2022. The study is a GLP-study to complement a previous investigation as part of our drug safety assessment program for Rabeximod.

GLP denotes a certain quality level – Good Laboratory Practice – that assures the highest data quality. Due to the high demand, GLP studies typically require long term planning in order to acquire appropriate time slots at a very limited number of specialist research service providers. The experienced Cyhone team did a stellar job in engaging a top service provider to conduct this important study during the winter of 2022-23. Having settled to start this GLP study in the near term, the original study plan has during the course of the experiments gone through some revisions which have resulted in a slightly prolonged study duration.

During the initiation phase of Cyxone's Phase 2 study in Covid-19, in 2021, the interactions with FDA were very instructive. The feedback we received from the agency was highly influential on important parameters of the study protocol, which resulted in the implementation of changes that impacted the study and the ongoing patient recruitment process. We have therefore learnt that securing FDA's feedback will be important also for the APPRAIS study.

Key activities in optimizing cost effectiveness in manufacturing

As part of the continued development of both Rabeximod and T20K, we are conducting a range of activities to establish more cost-effective manufacturing procedures. This work is carried out in collaboration with leading contract development and manufacturing organizations. For T20K we have currently been able to establish a process that enables the production of substance for the upcoming non-clinical and clinical development activities. For Rabeximod the work will be more extensive since the objective is to establish a value adding scalable process for the late-stage development and commercialization.

The Patent portfolio is maturing

One of the more important value building activities for the company is the continued expansion and maturation of the patent portfolio. Cyxone is working with different patent law firms and experts, each experts in their respective fields, in order to advance the patent portfolio in an international setting. Recently we could communicate about the national phase conversions of four of our PCT (Patent Convention Treaty) applications. Cyxone's patent applications are being submitted to a range of different countries representing important future markets, such as USA and European countries. The national phase conversion is an important milestone in the patent process strengthening company value.

World events

The macroeconomic effects of world events have great implication on the life science innovation industry. The willingness to take risks in the investor collective has been greatly impacted by the economic slowdown. This affects our industry with the significantly decreased valuations and opportunities for funding. In Cyxone we are working broadly, exploring various avenues for fundraising. We have committed to a range of non-dilutive funding opportunities to seek support for some of our R&D activities. We are also very busy with several business-to-business interactions to establish fruitful collaborations for future deals. We see that there is great interest in our projects and the planned R&D activities, and I am confident that we will be able to build on this in a positive way. We are also looking onwards with great optimism on the stock market trends and the ongoing recovery. The recent signals from both US and Swedish biotech indexes indicate positive sentiments on the market.

Please follow the company's development and our participation in investor meetings via Nasdaq First North Growth Market and on the company's website, www.cyxone.com

Carl-Magnus Högerkorp
CEO
Cyxone AB

Cyhone AB

Operations

Cyhone is a clinical-stage biotech company focusing on developing new life-changing solutions for patients suffering from severe autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS).


Rabeximod for rheumatoid arthritis (RA)

Cyhone is developing Rabeximod, an oral candidate drug for patients with moderate to severe active arthritis. Rabeximod's effect is based on inhibiting the activation of monocytes to form pro-inflammatory macrophages. Previous clinical data from a Phase 2a study in rheumatoid arthritis have demonstrated a favourable safety profile, confirmed optimal dose and therapeutic effect. Rabeximod is an oral substance with a new and unique mechanism of action which has the potential to contribute to a safer and more attractive complement to available treatments and to improve the quality of life for those who are affected.

Cyhone's intention is to position Rabeximod where it can create best value for those affected by rheumatoid arthritis. Rabeximod will be used as an early treatment, alone or in combination with other DMARDs. By potentially postponing the use of biologicals, which so far have proven to have undesired side effects, Rabeximod provides the possibility to achieve good quality of life for a longer period of time.

T20K for multiple sclerosis (MS)

T20K is a peptide that in preclinical models reduces an experimental course of disease and affect an important pathogenic factor, IL-2, a well-known player in the process that leads to the break-down of myelin, i.e. the important sheath that protects nerve cells in the central nervous system. This indicates that the drug candidate potentially could be effective in slowing down disease progression, preventing disease flares and postponing the need of second-line treatments in patients. T20K is currently in late preclinical stage.



This figure shows the current phase of each drug project.

Business model

Cyhone is well positioned with two unique projects, both of which are developed to achieve important and potential value-creating milestones. The purpose is to develop drugs that benefit patients and the healthcare system as well as the shareholders. Cyhone's goal is to outlicense projects to partners after Phase 2 clinical trials.

Management and Board of Directors

Cyhone's executive management team consists of experienced people with solid knowledge in the fields of drug development, business development and financing in innovative development companies. Members of the Cyhone board have extensive experience of taking projects from academic research stage to publicly traded development companies, fundraising as well as negotiating license and cooperation agreements.

Aims

Cyhone's aims are to develop therapies for autoimmune diseases which improves the quality of life and reduces side effects in patients based on the latest scientific data on the disease mechanism. The company's therapies are not only designed to be effective but are also aimed to be more convenient for patients to use, and to have fewer and milder side effects suitable for long-term use.

Vision

Cyhone's vision is to provide patients with transformative therapies for autoimmune (inflammatory) diseases, such as rheumatoid arthritis (RA) and multiple sclerosis (MS).

Strategy

Cyhone's long-term strategy is to develop Rabeximod and T20K to market approval in collaboration with external partners and to extend the pipeline by exploring further indications for its existing drug candidates and by inlicensing and acquisition of projects from external sources. As the company is in a growth phase, we remain open to the possibility of taking our programs through market approval in the future on our own.

Financial information

The Group

Group's turnover and results for the period January - December 2022

Turnover amounted to 0.0 MSEK (0.0)

Capitalized work on own account amounted to 6,4 MSEK (0.0). The operating cost amounted to 48,8 MSEK (45.0)

The overall loss for the group was -42,4 MSEK (-45.0).

Group's turnover and results for the period October - December 2022

Turnover amounted to 0.0 MSEK (0.0)

Capitalized work on own account amounted to 2.0 MSEK (0.0). The operating cost amounted to 8.2 MSEK (14.0) The overall loss for the group was -6.2 MSEK (-14.0).

Cash flow, liquidity and financial position, Group, for the period January - December 2022

Cash and cash equivalents at the end of the period amounted to 29.2 MSEK, compared with 29.4 MSEK at the end of the period. Total Equity amounts to 46.9 MSEK (39.2).

Cash flow for the period was -0.2 MSEK (-27.1), of which cash flow from operating activities amounted to a -41.3 MSEK (-43.3). Cash flow from investments amounted to -8.5 MSEK (-0.9). Cash flow from financing activities amounted to 45.5 MSEK (17.1).

At the end of the period, the equity ratio for the Group was 89.5 percent, compared with 85.0 percent at the end of December 2021.

Investments

Investments in tangible fixed assets amounted to 0.2 MSEK (0.0).

Parent Company

The Parent Company's turnover and results and financial position for the period January – December 2022

Turnover amounted to 0.0 MSEK (0.0)

Capitalized work on own account amounted to 6,4 MSEK (0.0) and operating cost to 48,7 MSEK (44,9). The Parent Company's operating loss for the period was 42,3 MSEK (44,9)

Net financial cost amounted to 0.1 MSEK (0.0) and the loss after financial items was 42,4 MSEK. (45,1). Cash and cash equivalents at the end of the period amounted to 28,1 MSEK at the end of the period, compared to 28,4 MSEK 1 januari 2022.

The Parent Company's turnover and results and financial position for the period October – December 2022

Turnover amounted to 0.0 MSEK (0.0)

Capitalized work on own account amounted to 2.0 MSEK (0.0) and operating cost to 8.1 MSEK (13.9). The Parent Company's operating loss for the period was 6.2 MSEK (13.9).

Net financial cost amounted to 0.0 MSEK (0.2) and the loss after financial items was 6.2 MSEK (14.1).

The parent company's equity and share capital

The parent company's equity at the end of the period amounted to SEK 46.9 million, compared with SEK 39.2 million at the end of 2021.

Personnel

The average number of employees during the period is 9.7 (6.3), of which the number of employees in research and development consists of 4.0 (3.2) employees. At the end of the period, the Parent company and the Group had 7 employees.

The Share

The company was formed on 2015-07-13. The share has been traded since 2016-06-07 on Nasdaq First North Growth Market Stockholm under the name CYXO.

The number of outstanding shares at the end of the period amounted to 98,444,728 and the total share capital to SEK 7,429,789.50.

During the fiscal year, Cyxone carried out the new issue of shares with preferential rights for the Company's shareholders, with the support of authorization from the Annual General Meeting on May 16th, 2022. The rights issue was added to Cyxone approximately SEK 61 million before deductions for issue costs amounting to SEK 10.8 million. Approximately 25 percent of the Rights Issue was subscribed for with the support of subscription rights. In addition, approximately 3 percent of the Rights Issue was subscribed for without the support of subscription rights and approximately 63 percent of the Rights Issue was subscribed for by issue guarantors. In total, the Rights Issue was subscribed for approximately 91 percent. Through the Rights Issue, the share capital increases by SEK 2,623,974 to SEK 7,429,788 and the number of shares in the Company increases by 34,767,672 to 98,444,728 shares.

Largest shareholders 31st of December 2022

Owner	Number of shares	Share of votes and capital (%)
Avanza Pension	7,059,744	7.17
Ivar Nordqvist	3,291,155	3.34
Göran Ofsén	2,400,000	2.44
Nordnet Pensionsförsäkring AB	2,005,483	2.04
Oxypharma AB	1,916,372	1.95
Fornio AB*	1,788,732	1.82
Mikeoo Holding AB**	1,788,732	1.82
ABBMO Holding AB	1,619,078	1.64
Christian Pettersson	1,283,000	1.30
C & Son Invest AB	1,000,743	1.02
Other shareholders	74,291,689	75.46
Totalt number of shares	98,444,728	100.00

*Bert Junno owns 100% of the shares in Fornio AB. Bert Junno further owns 400,000 shares in Cyxone AB.

**Mikael Lindstam owns 100% of the shares in Mikeoo Holding AB. Mikael Lindstam further owns 62,500 shares in Cyxone AB.

Future prospects including significant risks and uncertainties

Cyxone is dependent on external capital to finance its operations. The opportunity to raise external capital can be affected by factors beyond the company's control, such as cyclical fluctuations and market fluctuations, which can make it more difficult or more expensive for the company to raise new capital. Negative study results or significant

delays can also affect the company's opportunities for financing.

Cyxone's ability to develop drug projects to the point where partnership agreements can be secured and a partner takes responsibility for the future development and commercialization of the project is crucial to the company's long-term financial strength and stability. No partnerships have been entered into so far. Negative study results can have a negative impact on the company's ability to attract potential partners. Market fluctuations and changed regulations can also affect the company's attractiveness in the market. Cyxone is developing three (two) projects in parallel with different indications in an attempt to spread this risk and broaden its product portfolio.

A research company like Cyxone is characterized by high operational and financial risk, as the projects in which the company is involved have both developmental, regulatory and commercial risks. In addition, the company's ability to attract and retain key people with both insight into the research area and relevant product development experiences is a significant risk. The company is actively working to improve its opportunities to both attract and retain such key people. During the period, Cyxone made several recruitments to ensure that key resources and skills are available within the company and thereby reduced the company's dependence on external consultants.

Cyxone operates in an international market whereupon the company is affected by exchange rate changes around the world. Cyxone is in many cases dependent on international subcontractors to carry out studies and production of materials, after which fluctuations in exchange rates can have a significant impact on the prices of both goods and services.

Cyxone is so far exclusively engaged in research and product development and thus there is always a risk that development results may deviate from expectations, which may have a negative impact on the company in the form of increased costs, delays and reduced opportunities or conditions for capital raising or licensing. The drug development industry is a highly regulated market with strict regulatory requirements. Cyxone is in several stages in the development process dependent on obtaining regulatory approval from various authorities. The company works within the framework of the regulatory framework regarding clinical trials and must comply with these rules, but changes in regulatory requirements and processes can affect the company's opportunities to obtain regulatory approval or lead to increased costs and delays in the development process. In short, the business is associated with risks related to factors such as drug development, competition, technological progress, patents, regulatory requirements and capital requirements.

The Group's operations are conducted primarily in the Parent Company, which is why risks and uncertainties pertain to both the Group and the Parent Company.

War in Ukraine and its effects

Russia's invasion of Ukraine has a global impact. The macroeconomic effects of what is happening in the world today have major consequences for the innovation industry in life science. The willingness to take risks in the investment collective has been strongly affected by the economic downturn. The board and management continuously monitor the situation in Ukraine. If any of the company's activities are deemed to be affected by the war, the company will inform the market.

Principles for the preparation of the interim report

The group was formed on July 30, 2019 when Cyxone AB formed the subsidiary Cyxone Switzerland AG. The Group prepares its financial reports in accordance with International Financial Reporting Standards (IFRS), as adopted for the application of the EU. See Note 1, accounting principles.

Condensed consolidated statement of profit or loss

KSEK	Note	2022-10-01 2022-12-31	2021-10-01 2021-12-31	2022-01-01 2022-12-31	2021-01-01 2021-12-31
Operating income					
Other income		-	-	-	18
Capitalized work on own account	5	1 971	-	6 399	-
Total operating income		1 971	0	6 399	18
Operating costs					
Other external costs		-4 911	-9 982	-35 749	-33 002
Personnel expenses		-2 625	-3 430	-10 580	-10 013
Amortisation of tangible and intangible assets	4	-617	-449	-2 241	-1 794
Other operating expenses		-34	-125	-264	-237
Total operating costs		-8 186	-13 985	-48 834	-45 045
Operating profit/loss		-6 215	-13 985	-42 435	-45 028
Financial income		-	-	-	-
Financial costs		-11	0	-33	0
Net financial items		-11	0	-33	0
Profit/loss before tax		-6 226	-13 985	-42 468	-45 028
Tax	1	-3	-3	1	-3
Profit/loss for the period		-6 227	-13 988	-42 467	-45 031
Profit/loss for the period attributable to:					
Parent Company shareholders		-6 227	-13 988	-42 467	-45 031
Profit/loss for the period		-6 227	-13 988	-42 467	-45 031
Earnings per share					
Before and after dilution (SEK)		-0,06	-0,22	-0,44	-0,73

Condensed consolidated statement of profit or loss and other comprehensive income

KSEK	Note	2022-10-01	2021-10-01	2022-01-01	2021-01-01
		2022-12-31	2021-12-31	2022-12-31	2021-12-31
Profit/loss for the period		-6 227	-13 988	-42 467	-45 049
Other comprehensive income					
Items that are or may be reclassified subsequently to profit or loss					
Exchange differences on foreign operations		-57	43	104	66
Other comprehensive income for the period		-57	43	104	66
Total comprehensive income for the period		-6 284	-13 945	-42 363	-44 983
Total comprehensive income for the period attributable to					
Parent Company shareholders		-6 284	-13 945	-42 363	-44 983
Total comprehensive income for the period		-6 284	-13 945	-42 363	-44 983
The number of outstanding shares at the end of the reporting period					
– Before and after dilution		98 444 728	63 677 056	98 444 728	63 677 056
The average number of outstanding shares at the end of the reporting period					
– Before and after dilution		96 444 396	63 677 056	95 770 292	61 416 214

Condensed consolidated statement of financial position

KSEK	Note	31-dec-22	31-dec-21
Assets	4		
Capitalized work on own account	5	6 399	-
Patents, licenses		13 727	13 953
Leased assets		1 477	-
Equipment and tools		170	-
Long-term receivables		340	19
Deferred tax		3	-
Total non-current assets		22 116	13 972
Prepayment supplier's		-	-
Trade receivables		-	-
Other current receivables		581	822
Prepaid expenses and accrued income		583	1 978
Cash and cash equivalents		29 246	29 357
Total current assets		30 411	32 157
Total assets		52 527	46 128
Equity			
Share capital		7 430	4 806
Other paid in capital		232 530	185 078
Reserves		133	28
Retained earnings including profit/loss for the period	5	-193 146	-150 680
Equity attributable to Parent Company shareholders		46 946	39 232
Total equity		46 946	39 232
Liabilities			
Long-term financial liability		721	-
Total long-term liabilities		721	0
Trade payables		1 842	3 215
Short-term financial liability		645	-
Other current liabilities		685	864
Accrued expenses and deferred income		1 688	2 817
Total current liabilities		4 860	6 897
Total liabilities		5 581	6 897
Total equity and liabilities		52 527	46 128

Condensed consolidated statement of changes in equity

KSEK	Equity attributable to the parent company's shareholders				Total equity
	Share capital	Other unrestricted equity	Revaluation reserve	Balanced profits incl. The result of the period	
Opening balance equity 2021-01-01	4 382	168 410	-38	-105 649	67 105
Total comprehensive income for the period					
Profit/loss for the period				-45 031	-45 031
Other comprehensive income for the period			66		66
Total comprehensive income for the period			66	-45 031	-44 965
Transactions with the Group's owners					
Total transactions with the Group's owners	424	16 668			17 092
Closing balance equity 2021-12-31	4 806	185 078	28	-150 680	39 232

KSEK	Equity attributable to the parent company's shareholders				Total equity
	Share capital	Other unrestricted equity	Revaluation reserve	Balanced profits incl. The result of the period	
Opening balance equity 2022-01-01	4 806	185 078	28	-150 680	39 232
Total comprehensive income for the period					
Profit/loss for the period				-42 467	-42 467
Other comprehensive income for the period			104		104
Total comprehensive income for the period			104	-42 467	-42 363
Transactions with the Group's owners					
Share issues	2 624	47 452			50 076
Total transactions with the Group's owners	2 624	47 452			50 076
Closing balance equity 2022-12-31	7 430	232 530	132	-193 147	46 946

The amounts for share issues are reported net after deductions for transaction costs of 10.767 (1.097) KSEK.

Condensed consolidated statement of cash

KSEK	Note	2022-10-01	2021-10-01	2022-01-01	2021-01-01
		2022-12-31	2021-12-31	2022-12-31	2021-12-31
Operating activities					
Profit/loss before tax		-6 226	-13 985	-42 468	-45 028
Adjustment for non-cash items, etc					
Amortisation of intangible assets		449	449	1 794	1 794
Amortisation of tangible assets		168		447	
		-5 612	-13 540	-40 232	-43 254
Increase (-) / Decrease (+) of current receivables		-229	-724	1 635	-1 865
Increase (-) / Decrease (+) of current liabilities		-2 302	1 506	-2 727	1 850
Cash flow from operating activities		-8 142	-12 758	-41 323	-43 269
Investing activities					
Acquisition of intangible assets		-3 340	-892	-7 967	-892
Acquisition of tangible assets		0	0	-194	0
Acquisition of financial assets		0	0	-321	0
Cash flow from investing activities		-3 340	-892	-8 483	-892
Financing activities					
Share issues		0	0	60 845	18 188
Share issue costs		0	0	-10 767	-1 096
Financial liability		-158	0	-533	0
Cash flow from financing activities		-158	0	49 543	17 092
Total cash flow for the period		-11 640	-13 650	-263	-27 069
Cash and cash equivalents at the beginning of the period		40 889	42 963	29 357	56 343
Exchange rate difference in cash and cash equivalents		-3	44	153	65
Cash and cash equivalents at the end of the period		29 246	29 357	29 246	29 357

Condensed income statement for the parent company

KSEK	Note	2022-10-01	2021-10-01	2022-01-01	2021-01-01
		2022-12-31	2021-12-31	2022-12-31	2021-12-31
Operating income					
Other income		0	0	0	18
Capitalized work on own account		1 971	-	6 399	-
Total operating income		1 971	-	6 399	-
Operating costs					
Other external costs		-5 023	-9 919	-36 078	-32 892
Personel costs		-2 625	-3 430	-10 580	-10 013
Amortisation of intangible assets		-458	-449	-1 819	-1 794
Other operating costs		-34	-125	-264	-237
Total operating costs		-8 139	-13 923	-48 741	-44 936
Operating profit/loss		-6 168	-13 923	-42 342	-44 918
Profit/loss from financial items:		-11	-160	-11	-160
Write-down of financial fixed assets		0	0	0	0
Profit/loss before tax		-6 178	-14 082	-42 353	-45 078
Tax		0	0	0	-
Profit/loss for the period		-6 178	-14 082	-42 353	-45 078
Earnings per share for the parent company					
Before and after dilution (SEK)		-0,06	-0,22	-0,44	-0,73

Condensed income statement and other comprehensive income for the parent company

KSEK	Note	2022-10-01	2021-10-01	2022-01-01	2021-01-01
		2022-12-31	2021-12-31	2022-12-31	2021-12-31
Profit/loss for the period		-6 178	-14 082	-42 353	-45 078
Total comprehensive income for the period		-6 178	-14 082	-42 353	-45 078

Condensed balance sheet for the Parent company in summary

KSEK	Note	31-dec-22	31-dec-21
Assets	4		
Non-current assets			
Capitalized work on own account	5	6 399	-
Patents, licenses		13 727	13 953
Tangible assets		170	-
Financial assets:			
Participation in group companies		784	795
Long-term receivables		340	19
Total financial assets		1 124	814
Total non-current assets		21 420	14 767
Current assets			
Prepayment supplier's		-	-
Current receivables:			
Trade receivables		-	-
Receivables from group companies		297	139
Other current receivables		580	821
Prepaid expenses and accrued income		709	1 978
Total current receivables		1 586	2 938
Cash and bank		28 111	28 372
Total current assets		29 697	31 309
Total assets		51 117	46 076
Equity and liabilities	4		
Equity			
Restricted equity			
Share capital		7 430	4 806
Development reserve	5	6 399	-
Non-restricted equity			
Share premium reserve		232 530	185 078
Retained earnings		-157 049	-105 571
Profit/loss for the period		-42 353	-45 078
Total equity		46 957	39 234
Current liabilities			
Trade payables		1 829	3 215
Other current liabilities		683	864
Accrued expenses and deferred income		1 648	2 763
Total current liabilities		4 160	6 842
Total equity and liabilities		51 117	46 076

Notes to the condensed interim financial statements

Note 1 Accounting principles

This quarterly report has been prepared according to the IFRS standards that have been adopted by EU as well as the interpretations of the valid standards adopted by EU, IFRICs. This report for the Group has been prepared according to IAS 34, Interim financial reporting as well as applicable regulations in the Annual Accounts Act. The parent company quarterly report has been prepared according to chapter 9 in the Annual Accounts Act, Quarterly reports and RFR 2, Accounting rules for legal entities. The quarterly report has been prepared for the Group and parent company according to the same accounting principles and conditions applied in the latest Annual Report, except for the amended accounting principles described below.

In addition to the financial reports and their accompanying notes further information according to IAS 34.16A can be found in other sections of the quarterly report.

Note 2 Fair value for financial Instruments

Carrying amount is considered to be a reasonable approximation of fair value for all of the Group's financial instruments.

Note 3 Related party transactions

The board member Theresa Comiskey Olsen has during the financial year assisted the company with legal services via her related company. Remuneration for the services amounted to 79.4 (95.6) KSEK for the period January to December 2022. The board has decided to employ board member Mikael Lindstam during the financial year to assist the company with work in investor relations. The compensation for these services amounted to 142.5 KSEK for Mikael Lindstam during the period January - May. The board has decided to employ Chairman of the Board Bert Junno during the financial year to assist the company with work in investor relations, business development and financing of the company. The compensation for these services amounted to 450 KSEK for Bert Junno during the period April-December. CFO Ola Skanung has invoiced CFO services 174 KSEK for the period November-December and advisory services 282 KSEK for the period January-October.

Note 4 IFRS 16 leasing agreement

The new leasing agreement regarding office premises means that the group's income statement as of December 31 2022 has been affected by the fact that depreciation has increased by approximately 0.42 MSEK and financial costs have increased by approximately 0.03 MSEK. In the balance sheet, tangible fixed assets have increased by approximately 1.48 MSEK, leasing liabilities by approximately 1.37 MSEK.

Note 5 Capitalized work on own account

Capitalization of developmental expenses

During Q3 2022 Cyxone received regulatory approval for the start of clinical phase 2b study in RA. After obtaining the approval the board and management made the assessment that the criteria for capitalizing developmental expenditures according to IAS 38 have been met. During the second half of 2022, the development costs for RA that met the activation criteria amounted to 6 399 KSEK. In the report for Q4, the Q3 period is therefore adjusted as a result of 4 428 KSEK being capitalized. The change results in the group's profit after tax for the third quarter of 2022 changing from -11 274 KSEK to -6 846 KSEK

Correction of Q3

During Q3 in 2022, developmental expenditures for the RA project that met the capitalization criteria amounted to 4,428 KSEK, during Q4 the developmental expenditures for RA that met the activation criteria amounted to 1,971 KSEK. In the Q3 interim report, which was published on October 27, 2022, these development costs were not presented as an asset but as a cost, which has been corrected in this year-end report. 4.4 MSEK has been reported as income on the line Capitalized work on own account. The corresponding amount has been reported as Balanced development costs. The adjustment entails that the group's profit after tax for the third quarter of 2022 changed from -11,274 KSEK to -6,846 KSEK. In addition, earnings per share before and after dilution for the third quarter of 2022 have been calculated to 0.07 SEK per share compared to -0.11 SEK per share as presented in the published report. In the parent company, an amount of SEK 6,399 KSEK has been transferred from Balanced income to Fund for development expenses, meaning from non-restricted equity to restricted equity.

Certified Adviser

The company's Certified Adviser on Nasdaq First North Growth Market is FNCA AB.

Auditing

This report has not been reviewed by the company's auditors.

Legal disclaimer

This report contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this report.

Financial calendar

2023

27 th of April	Annual Report 2022
12 th of May	Interim Report Q1, 2023
30 th of May	Annual General Meeting 2023
30 th of August	Half Year Report, 2023
27 th of October	Interim Report Q3, 2023

2024

23rd of February Year-end Report, 2023

The reports will be available from these dates at www.cyxone.com: [Cyxone » Financial Reports](#)

Submission of Year-end report

The report for the period January – December 2022 provides a true and fair view of the Parent Company's and the Group's operations, position and results, and describes significant risks and uncertainties that the Parent Company and Group companies face.

Malmö

February 17, 2023

The Board of Directors

Cyxone AB

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com